ProKidney reports Q1 net loss $35.3M, cash $329M; Phase 2 data to be presented May 25

PROKIDNEY CORP.

RMCL-002 Phase 2 final results to be presented at ERA Congress on May 25, 2024; investor call on May 28.
PROACT 1 protocol amendment submitted to FDA focusing on severe CKD (eGFR 20-35); enrollment to resume mid-2024.
Appointed Ulrich Ernst as EVP Technical Operations and Lucio Tozzi as SVP Global Clinical Operations.
Cash and equivalents $329M as of March 31, 2024, supporting operations into Q4 2025.
Net loss before noncontrolling interest $35.3M for Q1 2024 vs $36.9M same period 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PROKIDNEY CORP. reported financial results for the first quarter ended March 31, 2024.

Period: the first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 10, 2024, ProKidney Corp. issued a press release to announce its financial results for the quarter ended March 31, 2024.

View on SEC.gov

1048 earnings releases filed in the last 30 days. Browse all earnings releases →

PROKIDNEY CORP. filing history →

Source: SEC EDGAR

accession 0000950170-24-057443

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.